Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single- strand conformation polymorphism analysis

Therapeutic Drug Monitoring

Volumn 22, Issue 3, 2000, Pages 237-244

  Ieiri, Ichiro ^a   Tainaka, Hitoshi ^b   Morita, Toshihiro ^a   Hadama, Atsuko ^c   Mamiya, Kohsuke ^c   Hayashibara, Masakazu ^a   Ninomiya, Hideaki ^c   Ohmori, Shigeru ^d   Kitada, Mitsukazu ^d   Tashiro, Nobutada ^c   Higuchi, Shun ^c   Otsubo, Kenji ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Asahi Techno Glass Corporation   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Catalytic activity; CYP2C9; New variant; Single strand conformation polymorphism (SSCP) analysis

Indexed keywords

AMINO ACID; DICLOFENAC; ISOLEUCINE; LEUCINE; PHENYTOIN; THREONINE;

ADULT; CASE REPORT; CATALYSIS; DNA DETERMINATION; EPILEPSY; GENOTYPE; HUMAN; IMMUNOBLOTTING; MALE; MICROSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADULT; ALLELES; AMINO ACID SUBSTITUTION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CATALYSIS; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; EPILEPSY; HUMANS; ISOENZYMES; ISOLEUCINE; KINETICS; LEUCINE; MALE; MIDDLE AGED; MUTAGENESIS, SITE-DIRECTED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECOMBINANT PROTEINS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; THREONINE; VARIATION (GENETICS);

EID: 0034041373     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200006000-00001     Document Type: Review

References (34)

1. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
2. Goldstein JA, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4: 285-99.
3. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
4. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P-450 CYP2C9 locus. Pharmacogenetics 1996;6:429-39.
5. Haining RL, Hunter AP, Veronese ME, Trager WF, Rerrie AE. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447-58.
6. Mamiya K, Ieiri I, Shimamoto J et al. The effects of genetic polymorphism of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: Studies in stereoselective hydroxylation and population pharmacokinetics. Epilepsia 1998; 39:1317-23.
7. Takahashi H, Kashima T, Nomoto S et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998;8:365-73.
8. Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000;10:85-9.
9. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992;267:83-90.
10. Wang SL, Huang JD, Lai MD, Tsai JJ. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics 1995;5:37-12.
11. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19 and CYP2C9, in a Japanese population. Ther Drug Monit 1998;20:243-7.
12. Hayashi K, PCR-SSCP: a simple and sensitive method for detections of mutations in the genomic DNA. PCR Methods App 1991; 1:34-8.
13. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989;5:874-9.
14. Yasumori T, Kawano S, Nagata K, Shimada M, Yamazoe Y, Kato R. Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. J Biochem (Tokyo) 1987;102:1075-82.
15. Giga-Hama Y, Tohda H, Okada H, Owada MK, Okayama H, Kumagai H. High-level expression of human lipocortin I in the fission yeast Schizosaccharomyces pombe using a novel expression vector. Biotechnology 1994;12:400-4.
16. Russell PR, Hall BD. The primary structure of the alcohol dehydrogenase gene from the fission yeast Schizosaccharomyces pombe. J Biol Chem 1983;258:143-9.
17. Okazaki K, Okazaki N, Kume K, Jinno S, Tanaka K, Okayama H. High-frequency transformation method and library transducing vectors for cloning mammalian cDNAs by trans-complementation of Schizosaccharomyces pombe. Nucleic Acid Res 1990;18: 6485-9.
18. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239:531-7.
19. Phillips AH, Langdon RG. Hepatic triphosphopyridine nucleotidecytochrome c reductase: Isolation, characterization and kinetic studies. J Biol Chem 1962;237:2652-60.
20. Ohmori S, Chiba K, Nakasa H, Horie T, Kitada M. Characterization of monkey cytochrome P450, P450CMLd, responsible for S-mephenytoin 4′-hydroxylation in hepatic microsomes of cynomolgus monkeys. Arch Biochem Biophys 1994;311:395-401.
21. Yamazaki H, Inoue K, Chiba K et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys-and Leuvariants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998;56:243-51.
22. Crespi CL, Miller VP, The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203-10.
23. Yukawa E, Higuchi S, Aoyama T. Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update. Chem Pharm Bull 1990;38:1973-6.
24. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet 1994; 26:59-70.
25. Miners JO, Rees DLP, Valente L, Verosese ME, Birkett DJ. Human hepatic cytochrome P450 2C9 catalyses the rate-limiting pathway of torsemide metabolism. J Pharmacol Exp Ther 1995;272: 1076-81.
26. Bhasker CR, Miners JO, Coulter S, Birkett DJ, Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997;7:51-8.
27. Spielberg S, McCrea J, Cribb A, Rushmore T, Waldman S, Bjornsson T, Lo MW, Goldberg M. A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clin Pharmacol Ther 1996; 59: 215.
28. Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999;9:71-80.
29. Shen S, Strobel HR. The role of cytochrome P450 lysine residues in the interaction between cytochrome P4501A1 and NADPH-cytochrome P450 reductase. Arch Biochem Biophys 1992;294:83-90.
30. Von Wachenfeldt C, Johnson EF. Structures of eukaryotic cytochrome P450 enzymes. In: Oritz de Montellano PR. ed. Cytochrome P450 Structure, mechanism and biochemistry. New York: Plenum Press; 1995:183-223.
31. Klose TS, Ibeanu GC, Ghanayem BI, et al. Identification of residue 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen. Arch Biochem Biophys 1998;357:240-8.
32. Laughton CA, Neidle S, Zvelebil MJ, Sternberg MJ. A molecular model for the enzyme cytochrome P450 (17 alpha), a major target for the chemotherapy of prostatic cancer. Biochem Biophys Res Commun 1990;171:1160-7.
33. Lindberg RLP, Negishi M. Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature 1986;339:632-4.
34. Broly F, Marez D, Sabbagh N et al. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single-strand conformation polymorphism analysis. Pharmacogenetics 1995;5:373-84.